Delfi Diagnostics outlined a roadmap at JPM for multiple pivotal readouts in 2026 tied to FirstLook Lung, its cfDNA fragmentomics lung‑cancer screening assay, and flagged plans to use those data for reimbursement and regulatory submissions. The company expects registrational data from its CASCADE‑LUNG study to support an FDA premarket approval filing toward the end of 2026. In parallel, the BloodPAC consortium published analytic validation protocols for tumor‑informed ctDNA MRD assays to harmonize limit-of-detection, accuracy and robustness testing. The new standards aim to accelerate assay comparability and clinical adoption—critical steps for MRD and screening tests seeking guideline inclusion and payer coverage.